D
Denali Therapeutics Inc. (DNLI)
18.16
0.00 (0.00%)
Get all premium features to the best stock analysis tool
18.16
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 9.16 | 6.05 | 10 | |
| Quick ratio | 9.16 | 5.63 | 10 | |
| Debt to Equity | 0.04 | 0.30 | 9.0 | |
| Debt to Assets | 0.04 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 108M | 331M | N/A | N/A | N/A |
| Gross Profit | 101M | 314M | -8M | -15M | -12M |
| Operating Income | -341M | -197M | -502M | -555M | -555M |
| Net Income | -326M | -145M | -423M | -513M | -513M |
| EBITDA | -334M | -180M | -494M | -541M | -543M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | N/A | 15.15 | 5.0 |
| Next quarter | N/A | 12.6 | 4.5 |
| Current year | N/A | 8.45 | 3.5 |
| Next year | 163.41 | 8.59 | 8.0 |
| Weighted average score | 5.3 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | -1.29 | 1.35 | 5.53 | 4.8 |
| Y/Y | 999 | -12.01 | -8.95 | -12.66 | 3.3 |
| 3y average | 367.92 | -52.28 | -32.91 | -18.45 | 3.3 |
| 5y average | 228.23 | -135.5 | -117.37 | -45.59 | 3.3 |
| Weighted average score | 3.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $205.3M significantly exceed its total debt $42.3M, ensuring strong financial flexibility
Total current assets $900.7M exceed Total current liabilities $98.4M, highlighting excellent liquidity
Debt-to-equity ratio (0.0) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$100.1M limits the company's ability to reinvest or pay down debt